Our core business focuses on the development of genetics and the production of seeds and proprietary cultivars, within a framework of R&D programs.
Our experience and knowledge, and the leadership obtaining required permits as producer and supplier of registered cannabis genetics, places the company in a privileged position for global operations.
Two pillars underpin medcann’s creation in 2016:
Profound understanding of the regulatory framework.
Decades of expertise in cannabis cultivation, hybridization and transformation for medical purposes.
As from 2021, the company focuses its endeavors and strategy on cannabis genetics to provide the highest quality, legal and formalized genetic varieties to the global market.
medcann Pharma envisions itself as leading supplier for both the medical cannabis and hemp industry worldwide, maintaining a broad spectrum of cannabis genetics in our portfolio. We will be continually increasing diversity through R&D to meet the market needs, utilizing the latest molecular genomics technology.
(chemovars, productivity, and resilience)